Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 85-92 , March 2008

Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML)

  • Frederick R. Appelbaum, MD (Director of the Clinical Research Division, Head of the Division of Oncology)

      Affiliations

    • Corresponding Author InformationTel.: +1 206 667 4412; Fax: +1 206 667 6936.

References 

  1. Davies SM, Rowe JM, Appelbaum FR. Indications for hematopoietic cell transplantation in acute leukemia. Biol Blood Marrow Transplant, in press.
  2. Yanada M, Matsuo K, Emi N, et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103:1652–1658
  3. Schlenk RF, Corbacioglu A, Krauter J, et al. Gene mutations as predictive markers for postremission therapy in younger adults with normal karyotype AML. Blood. 2006;108:6a;[abstract 4]
  4. Levi I, Grotto I, Yerushalmi R, et al. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leukemia Research. 2004;28:605–612
  5. Krauter J, Heil G, Hoelzer D, et al. Role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood. 2005;106:54a;[abstract 172]
  6. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. The New England Journal of Medicine. 2004;351:2276–2285
  7. Center for International Blood and Marrow Transplant Research . Available from: www.cibmtr.org2007;[accessed 9.05.07]. Ref Type: Electronic Citation
  8. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. Journal of Clinical Oncology. 1992;10:1723–1729
  9. Brown RA, Wolff SN, Fay JW, et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood. 1995;85:1391–1395
  10. Schiffman K, Clift R, Appelbaum FR, et al. Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. Bone Marrow Transplantation. 1993;11:227–232
  11. Rowe JM, Li X, Cassileth PA, et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: the Eastern Cooperative Oncology Group Experience. Blood. 2005;106:162a;[abstract 546]
  12. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood. 2003;101:2521–2528
  13. San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746–1751
  14. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. British Journal of Haematology. 2003;123:243–252
  15. Feller N, van der Pol MA, van SA, et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia. 2004;18:1380–1390
  16. Venditti A, Buccisano F, Del PG, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96:3948–3952
  17. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006;20:1783–1789
  18. Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003;101:3398–3406
  19. Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Archives of Pathology & Laboratory Medicine. 2006;130:680–690

PII: S1521-6926(07)00102-8

doi: 10.1016/j.beha.2007.11.013

Best Practice & Research Clinical Haematology
Volume 21, Issue 1 , Pages 85-92 , March 2008

Article Tools

* Image Usage & Resolution